Evaluation of Cirrhosis and Malignant Hepatic Lesions Using Novel MR Contrast Agents

Inclusion Criteria:

- Alpha-feto protein > 400 ng / mL or

- prior ultrasound with mass suspicious for hepatic malignancy or.

- clinical risk of hepatocellular carcinoma or

- prior multi-detector CT with mass suspicious for possible hepatocellular carcinoma

Exclusion Criteria:

- Glomerulo-filtration rate < 50 mL/ min/1.73 m2 based on a creatinine measurement
within three months of the MR study

- Previous diagnosis of hepatic malignancy

- Any conditions that would discount the ability to have an MRI scan